Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

Phase 2

• Conditions: Anosmia
• Interventions: Drug: intranasal spray ivermectin

• Registration Number: NCT04951362
• Lead Sponsor: South Valley University

Brief Summary

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Detailed Description

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Study Timeline

• Study Start: 2021-04-20
• Study First Submitted: 2021-06-30
• Study First Submitted QC: 2021-07-01
• Study First Posted: 2021-07-06
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-14
• Last Update Posted: 2022-04-22
• Primary Completion: 2022-05-12
• Study Completion: 2022-05-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

• post covid19 anosmia
• negative swab test for covid19

Exclusion Criteria

• other types of anosmia ,
• no local or central other causes of anosmia
• still active covid 19 pateints ( positive swab test )

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
intranasal Ivermectin group	intranasal spray ivermectin	49 pateints with anosmia received ivermectin nanosuspension nasal spray
saline nasal spray	intranasal spray ivermectin	47 pateints with anosmia received saline nasal spray

Primary Outcome Measures

Name	Time	Method
regaining of smell	within 14 days after enrollemen ]	regaining of smell

Trial Locations

Locations (1)

Zaky Aref; 🇪🇬 Qina, Egypt